HuCC-T1 Cells

HuCC-T1 is a human cholangiocarcinoma cell line established from an intrahepatic bile duct carcinoma. Cholangiocarcinoma is a highly aggressive malignancy with limited treatment options and a poor prognosis. HuCC-T1 cells have been utilized extensively in research to study the pathophysiology of cholangiocarcinoma and to explore potential therapeutic approaches. The cell line is particularly valuable in studying the effects of various chemotherapeutic agents, including statins, which have shown potential in suppressing the proliferation of cholangiocarcinoma cells.

In studies involving HuCC-T1, statins such as pitavastatin and atorvastatin were observed to significantly inhibit cell proliferation, particularly when combined with conventional chemotherapeutic agents like gemcitabine, cisplatin, and 5-fluorouracil (5-FU). The combination of these drugs resulted in enhanced suppression of cell growth, indicating potential synergistic effects. The mechanism of action involves the induction of apoptosis via suppression of the MAPK/ERK signaling pathway, as evidenced by increased levels of cleaved caspase-3 and reduced levels of phosphorylated ERK (p-ERK). These findings suggest that statins may serve as a promising adjunct therapy in the treatment of cholangiocarcinoma, potentially improving outcomes when used alongside existing anticancer drugs.

Furthermore, the HuCC-T1 cell line has been characterized for various molecular markers, including p53 gene status, which plays a critical role in cell cycle regulation and apoptosis. The precise p53 mutation status in HuCC-T1 could provide insights into the cell line’s response to DNA-damaging agents and its overall tumorigenic potential. Given its molecular characteristics, HuCC-T1 continues to be a pivotal tool in cholangiocarcinoma research, offering insights into the disease’s molecular underpinnings and aiding in the development of novel therapeutic strategies.